These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 9044824

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Receptor-bound uPA is reversibly protected from inhibition by low molecular weight inhibitors.
    Dyer KD, Linz-Mcgillem LA, Alliegro MA, Alliegro MC.
    Cell Biol Int; 2002; 26(4):327-35. PubMed ID: 11991662
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Inhibitory effect of amiloride on the urokinase plasminogen activators in prostatic cancer.
    Ray P, Bhatti R, Gadarowski J, Bell N, Nasruddin S.
    Tumour Biol; 1998; 19(1):60-4. PubMed ID: 9422083
    [Abstract] [Full Text] [Related]

  • 26. Regulated localization confers multiple functions on the protease urokinase plasminogen activator.
    Wells JM, Strickland S.
    J Cell Physiol; 1997 May; 171(2):217-25. PubMed ID: 9130470
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Targeting uPA/uPAR in prostate cancer.
    Li Y, Cozzi PJ.
    Cancer Treat Rev; 2007 Oct; 33(6):521-7. PubMed ID: 17658220
    [Abstract] [Full Text] [Related]

  • 34. The invasive behaviour of prostatic cancer cells is suppressed by inhibitors of tyrosine kinase.
    Skogseth H, Larsson E, Halgunset J.
    APMIS; 2006 Jan; 114(1):61-6. PubMed ID: 16499663
    [Abstract] [Full Text] [Related]

  • 35. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K, Miyata Y, Kanda S, Koga S, Hayashi T, Kanetake H.
    J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. The urokinase-type plasminogen activator system in prostate cancer metastasis.
    Sheng S.
    Cancer Metastasis Rev; 2001 Aug; 20(3-4):287-96. PubMed ID: 12085967
    [Abstract] [Full Text] [Related]

  • 39. Natural and synthetic inhibitors of the tumor-associated serine protease urokinase-type plasminogen activator.
    Magdolen V, Arroyo de Prada N, Sperl S, Muehlenweg B, Luther T, Wilhelm OG, Magdolen U, Graeff H, Reuning U, Schmitt M.
    Adv Exp Med Biol; 2000 Aug; 477():331-41. PubMed ID: 10849761
    [No Abstract] [Full Text] [Related]

  • 40. 6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.
    Buckley BJ, Aboelela A, Minaei E, Jiang LX, Xu Z, Ali U, Fildes K, Cheung CY, Cook SM, Johnson DC, Bachovchin DA, Cook GM, Apte M, Huang M, Ranson M, Kelso MJ.
    J Med Chem; 2018 Sep 27; 61(18):8299-8320. PubMed ID: 30130401
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.